Find Golvatinib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 928037-13-2, E-7050, Golvatinib (e7050), E7050, Unii-516z3yp58e, Golvatinib (usan)
Molecular Formula
C33H37F2N7O4
Molecular Weight
633.7  g/mol
InChI Key
UQRCJCNVNUFYDX-UHFFFAOYSA-N
FDA UNII
516Z3YP58E

Golvatinib
Golvatinib is an orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factor receptor-2) tyrosine kinases with potential antineoplastic activity. c-Met/VEGFR kinase inhibitor E7050 binds to and inhibits the activities of both c-Met and VEGFR-2, which may inhibit tumor cell growth and survival of tumor cells that overexpress these receptor tyrosine kinases. c-Met and VEGFR-2 are upregulated in a variety of tumor cell types and play important roles in tumor cell growth, migration and angiogenesis.
1 2D Structure

Golvatinib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
1-N'-[2-fluoro-4-[2-[[4-(4-methylpiperazin-1-yl)piperidine-1-carbonyl]amino]pyridin-4-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
2.1.2 InChI
InChI=1S/C33H37F2N7O4/c1-40-16-18-41(19-17-40)24-9-14-42(15-10-24)32(45)39-29-21-26(8-13-36-29)46-25-6-7-28(27(35)20-25)38-31(44)33(11-12-33)30(43)37-23-4-2-22(34)3-5-23/h2-8,13,20-21,24H,9-12,14-19H2,1H3,(H,37,43)(H,38,44)(H,36,39,45)
2.1.3 InChI Key
UQRCJCNVNUFYDX-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CN1CCN(CC1)C2CCN(CC2)C(=O)NC3=NC=CC(=C3)OC4=CC(=C(C=C4)NC(=O)C5(CC5)C(=O)NC6=CC=C(C=C6)F)F
2.2 Other Identifiers
2.2.1 UNII
516Z3YP58E
2.3 Synonyms
2.3.1 MeSH Synonyms

1. E 7050

2. E-7050

3. E7050 Cpd

4. N-(2-fluoro-4-((2-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)carbonylaminopyridin-4-yl)oxy)phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

2.3.2 Depositor-Supplied Synonyms

1. 928037-13-2

2. E-7050

3. Golvatinib (e7050)

4. E7050

5. Unii-516z3yp58e

6. Golvatinib (usan)

7. Golvatinib [usan]

8. 1-n'-[2-fluoro-4-[2-[[4-(4-methylpiperazin-1-yl)piperidine-1-carbonyl]amino]pyridin-4-yl]oxyphenyl]-1-n-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

9. 516z3yp58e

10. N-[2-fluoro-4-[[2-[[[4-(4-methylpiperazin-1-yl)piperidin-1-yl]carbonyl]amino]pyridin-4-yl]oxy]phenyl]-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

11. Golvatinib Tartrate

12. Golvatinib [usan:inn]

13. N-(2-fluoro-4-{[2-({[4-(4-methylpiperazin-1-yl)piperidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

14. E7050;golvatinib

15. Golvatinib [inn]

16. E 7050

17. Golvatinib [who-dd]

18. Gtpl7956

19. Schembl1727298

20. Chembl3039525

21. Dtxsid40239155

22. Ex-a830

23. Chebi:177746

24. Hms3651j19

25. Bcp06122

26. Bdbm50100615

27. Mfcd22124462

28. Nsc800107

29. Nsc808608

30. S2859

31. Zinc43195317

32. Akos025404927

33. Ccg-270294

34. Cs-0595

35. Db11977

36. Nsc-800107

37. Nsc-808608

38. Sb16585

39. Ncgc00386210-06

40. Ac-30125

41. As-56994

42. Hy-13068

43. N-(2-fluoro-4-(2-(4-(4-methylpiperazin-1-yl)piperidine-1-carboxamido)pyridin-4-yloxy)phenyl)-n-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

44. B1439

45. Ft-0700410

46. Sw219690-1

47. D10224

48. E 7050;e7050

49. J-523320

50. Q27077829

51. 1,1-cyclopropanedicarboxamide, N-(2-fluoro-4-((2-(((4-(4-methyl-1-piperazinyl)-1- Piperidinyl)carbonyl)amino)-4-pyridinyl)oxy)phenyl)-n'-(4-fluorophenyl)-

52. 1,1-cyclopropanedicarboxamide, N-(2-fluoro-4-((2-(((4-(4-methyl-1-piperazinyl)-1-piperidinyl)carbonyl)amino)-4-pyridinyl)oxy)phenyl)-n'-(4-fluorophenyl)-

53. 1-n'-[2-luoro-4-[2-[[4-(4-methylpiperazin-1-yl)piperidine-1-carbonyl]amino]pyridin-4-yl]oxyphenyl]-1-n-(4-luorophenyl)cyclopropane-1,1-dicarboxamide

54. 1-n\'-[2-fluoro-4-[2-[[4-(4-methylpiperazin-1-yl)piperidine-1-carbonyl]amino]pyridin-4-yl]oxyphenyl]-1-n-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

55. Gv0

56. N'-[2-fluoro-4-[2-[[4-(4-methylpiperazin-1-yl)piperidine-1-carbonyl]amino]pyridin-4-yl]oxyphenyl]-n-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

57. N-(2-fluoro-4-((2-(((4-(4-methylpiperazin-1-yl)piperidin-1-yl)carbonyl)amino)pyridin-4- Yl)oxy)phenyl)-n'-(4- Fluorophenyl)cyclopropane-1,1-dicarboxamide

58. N-(2-fluoro-4-((2-(4-(4-methylpiperazin-1-yl)piperidine-1-carboxamido)pyridin-4-yl)oxy)phenyl)-n-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

59. N-[2-fluoro-4-[[2-[[[4-(4-methylpiperazin-1-yl)piperidin-1-yl]carbonyl]amino]pyridin-4-yl]oxy]phenyl]-n'-(4-fluorophenyl)cyclopropan E-1,1-dicarboxamide

60. N~1~-{2-fluoro-4-[(2-{[4-(4-methylpiperazin-1-yl)piperidine-1-carbonyl]amino}pyridin-4-yl)oxy]phenyl}-n'~1~-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

2.4 Create Date
2007-06-19
3 Chemical and Physical Properties
Molecular Weight 633.7 g/mol
Molecular Formula C33H37F2N7O4
XLogP34.1
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count9
Rotatable Bond Count8
Exact Mass633.28750901 g/mol
Monoisotopic Mass633.28750901 g/mol
Topological Polar Surface Area119 Ų
Heavy Atom Count46
Formal Charge0
Complexity1060
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

ABOUT THIS PAGE

Looking for 928037-13-2 / Golvatinib API manufacturers, exporters & distributors?

Golvatinib manufacturers, exporters & distributors 1

77

PharmaCompass offers a list of Golvatinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Golvatinib manufacturer or Golvatinib supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Golvatinib manufacturer or Golvatinib supplier.

PharmaCompass also assists you with knowing the Golvatinib API Price utilized in the formulation of products. Golvatinib API Price is not always fixed or binding as the Golvatinib Price is obtained through a variety of data sources. The Golvatinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Golvatinib

Synonyms

928037-13-2, E-7050, Golvatinib (e7050), E7050, Unii-516z3yp58e, Golvatinib (usan)

Cas Number

928037-13-2

Unique Ingredient Identifier (UNII)

516Z3YP58E

About Golvatinib

Golvatinib is an orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factor receptor-2) tyrosine kinases with potential antineoplastic activity. c-Met/VEGFR kinase inhibitor E7050 binds to and inhibits the activities of both c-Met and VEGFR-2, which may inhibit tumor cell growth and survival of tumor cells that overexpress these receptor tyrosine kinases. c-Met and VEGFR-2 are upregulated in a variety of tumor cell types and play important roles in tumor cell growth, migration and angiogenesis.

Golvatinib Manufacturers

A Golvatinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Golvatinib, including repackagers and relabelers. The FDA regulates Golvatinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Golvatinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Golvatinib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Golvatinib Suppliers

A Golvatinib supplier is an individual or a company that provides Golvatinib active pharmaceutical ingredient (API) or Golvatinib finished formulations upon request. The Golvatinib suppliers may include Golvatinib API manufacturers, exporters, distributors and traders.

click here to find a list of Golvatinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Golvatinib GMP

Golvatinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Golvatinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Golvatinib GMP manufacturer or Golvatinib GMP API supplier for your needs.

Golvatinib CoA

A Golvatinib CoA (Certificate of Analysis) is a formal document that attests to Golvatinib's compliance with Golvatinib specifications and serves as a tool for batch-level quality control.

Golvatinib CoA mostly includes findings from lab analyses of a specific batch. For each Golvatinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Golvatinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Golvatinib EP), Golvatinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Golvatinib USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty